Vertex, Inc. (NASDAQ:VERX), is not the largest company out there, but it led the NASDAQGM gainers with a relatively large price hike in the past couple of weeks. While good news for shareholders, the ...

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% ...

Vertex Pharmaceuticals (VRTX ... Elsewhere, the Dow gained 1.23%, while the tech-heavy Nasdaq added 2.74%. The drugmaker's shares have seen a decrease of 1.57% over the last month, surpassing ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance ...

Vertex (NASDAQ:VERX – Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported $0.10 EPS for the quarter, missing the consensus estimate of $0. ...

Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 18 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of ...

Meanwhile, for fiscal 2025, analysts expect Vertex Pharmaceuticals to report ... of the author and do not necessarily reflect those of Nasdaq, Inc. With headquarters in the heart of Chicago's ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex, Inc. (NASDAQ: VERX) has announced plans to release its first quarter 2025 financial results on Wednesday, May 7, 2025 ...

Shares of Vertex, Inc. (NASDAQ:VERX – Get Free Report) have received a consensus rating of “Moderate Buy” from the thirteen brokerages that are covering the stock, Marketbeat reports.

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% higher in price, on the back of two positive mentions by analysts ...